In light of the above in vitro synergistic anti-tumor effects of the combination treatment, we next generated two human CDH1-deficient cell line (SNU-668 and NUGC-4)-derived xenograft (CDX) models in mice to evaluate the potential in vivo therapeutic effects of the ROS1 inhibitor-IN10018 combination. This evidence concerns the gene ROS1 and neoplasm.